Advertisement

Investigational New Drugs

, Volume 30, Issue 3, pp 1257–1260 | Cite as

TRAIL shows potential cardioprotective activity

  • Barbara Toffoli
  • Stella Bernardi
  • Riccardo Candido
  • Serena Zacchigna
  • Bruno Fabris
  • Paola SecchieroEmail author
SHORT REPORT

Summary

Recent clinical trials carried out in patients with advanced cancer have shown that recombinant TRAIL administration is usually safe and well tolerated when used either alone or in association with chemotherapeutic drugs. Notably, anticancer chemotherapy can be associated to cardiomiopathy. We have here demonstrated that TRAIL (administrated as either recombinant soluble TRAIL or as AAV-TRAIL expression viral vector) reduced the development of cardiomyopathy in the ApoE-/- diabetic mouse model. These data suggest, for the first time, that therapeutically administration of TRAIL might have a cardioprotective effect.

Keywords

Diabetic Mouse Cardiac Fibrosis Diabetic Cardiomyopathy Left Ventricle Mass Cardiac Apoptosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This work was supported by a grant from “Programma di Ricerca Regione-Università 2007/2009” (Regione Emilia Romagna to P.S.) and from “Ministero dell’Università e della Ricerca Scientifica e Tecnologica” of Italy (to B.F.).

References

  1. 1.
    Herbst RS, Eckhardt SG, Kurzrock R et al (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28:2839–2846PubMedCrossRefGoogle Scholar
  2. 2.
    Soria JC, Smit E, Khayat D et al (2010) Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28:1527–1533PubMedCrossRefGoogle Scholar
  3. 3.
    Secchiero P, Zauli G (2008) TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Op Hematol 15:42–48CrossRefGoogle Scholar
  4. 4.
    Secchiero P, Corallini F, Ceconi C et al (2009) Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PloS One 4:e-4442CrossRefGoogle Scholar
  5. 5.
    Niessner A, Hohensinner PJ, Rychli K et al (2009) Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 30:789–796PubMedCrossRefGoogle Scholar
  6. 6.
    Mori K, Ikari Y, Jono S et al (2010) Association of serum TRAIL level with coronary artery disease. Thromb Res 125:322–325PubMedCrossRefGoogle Scholar
  7. 7.
    Di Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331–340PubMedCrossRefGoogle Scholar
  8. 8.
    Secchiero P, Corallini F, Beltrami PA et al (2010) An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 210:274–277PubMedCrossRefGoogle Scholar
  9. 9.
    Secchiero P, Candido R, Corallini F et al (2006) Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 114:1522–1530PubMedCrossRefGoogle Scholar
  10. 10.
    Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126–135PubMedCrossRefGoogle Scholar
  11. 11.
    Lipshultz SE, Scully RE, Lipsitz SR et al (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950–961PubMedCrossRefGoogle Scholar
  12. 12.
    Fabris B, Candido R, Bortoletto M et al (2007) Dose and time-dependent apoptotic effects by angiotensin II infusion on left ventricular cardiomyocites. J Hypertens 25:1481–1490PubMedCrossRefGoogle Scholar
  13. 13.
    Candido R, Forbes JM, Thomas MC et al (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92:785–792PubMedCrossRefGoogle Scholar
  14. 14.
    Secchiero P, Zerbinati C, Rimondi E et al (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965–1974PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Barbara Toffoli
    • 1
  • Stella Bernardi
    • 2
  • Riccardo Candido
    • 4
  • Serena Zacchigna
    • 5
  • Bruno Fabris
    • 6
  • Paola Secchiero
    • 3
    Email author
  1. 1.Institute for Maternal and Child HealthIRCCS Burlo GarofoloTriesteItaly
  2. 2.Diabetic Complications, Baker IDI Heart & Diabetes InstituteMelbourneAustralia
  3. 3.Department of Morphology and Embryology and LTTA CentreUniversity of FerraraFerraraItaly
  4. 4.Diabetic CentreA.S.S. 1 TriestinaTriesteItaly
  5. 5.Medicine LaboratoryInternational Center for Genetic Engineering and Biotechnology (ICGEB)TriesteItaly
  6. 6.Department of Medical, Technological and Translational SciencesUniversity of Trieste, Cattinara HospitalTriesteItaly

Personalised recommendations